Microenvironment and tumor progression of melanoma: New therapeutic prospectives

References

• Abe, K., Harada, M., Tamada, K., Ito, O., Li, T., Nomoto, K. 1998. Early-appearing tumor-infiltrating natural killer cells play an important role in the nitric oxide production of tumor-associated macrophages through their interferon production. Cancer Immunol. Immunother. 45:225–233.
   PubMedGoogle Scholar
• Adair-Kirk, T. L., Senior, R. M. 2008. Fragments of extracellular matrix as mediators of inflammation. Int. J. Biochem. Cell Biol. 40:1101–1110.
   PubMed Web of Science ®Google Scholar
• Aharinejad, S., Sioud, M., Lucas, T., Abraham, D. 2007. Target validation using RNA interference in solid tumors. Methods Mol. Biol. 361:227–238.
   PubMedGoogle Scholar
• Allavena, P., Sica A., Garlanda, C., Mantovani, A. 2008a. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol. Rev. 222:155–161.
   PubMed Web of Science ®Google Scholar
• Allavena, P., Sica, A., Solinas, G., Porta, C., Mantovani, A. 2008b. The inflammatory microenvironment in tumor progression: Role of tumor-associated macrophages. Crit. Rev. Oncol. Hematol. 66:1–9.
   PubMed Web of Science ®Google Scholar
• Allavena, P., Signorelli, M., Chieppa, M., Erba, E., Bianchi, G., Marchesi, F., Olimpio, C. O., Bonardi, C., Garbi, A., Lissoni, A., de Braud, F., Jimeno, J., D’Incalci, M. 2005. Anti-inflammatory properties of the novel anti-tumor agent yondelis (trabectedin): Inhibition of macrophage differentiation and cytokine production. Cancer Res. 65:2964–2971.
   PubMed Web of Science ®Google Scholar
• Ascierto, P. A., Berking, C., Agarwal, S. S., Schadendorf, D., van Herpen, C., Queirolo, P., Blank, C. U., Hauschild, A., Beck, J. T., Zubel, A., Niazi, F., Wandel, S., Dummer, R. 2012. Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. J. Clin. Oncol. 30 (Suppl): Abstract 8511.
   Google Scholar
• Ascierto, P. A., Streicher, H. Z., Sznol, M. 2010. Melanoma: A model for testing new agents in combination therapies. J. Transl. Med. 8:38.
   Google Scholar
• Balkwill, F., Mantovani, A. 2001. Inflammation and cancer: Back to Virchow? Lancet 357:539–545.
   PubMed Web of Science ®Google Scholar
• Bancherau, J., Steinman, R. M. 1998. Dendritic cells and the control of immunity. Nature 392:245–252.
   PubMed Web of Science ®Google Scholar
• Baronas-Lowell, D., Lauer-Fields, J. L., Borgia, J. A., Sferrazza, G. F., Al-Ghoul, M., Minond, D., Fields, G. B. 2004. Differential modulation of human melanoma cell metalloproteinase expression by α2β1 integrin and CD44 triple-helical ligands derived from Type IV collagen. J. Biol. Chem. 279:43503–43513.
   PubMedGoogle Scholar
• Benini, S., Perbal, B., Zambelli, D., Colombo, M. P., Manara, M. C., Serra, M., Parenza, M., Martinez, V., Picci, P., Scotlandi, K. 2005. In Ewing’s sarcoma, CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. Oncogene 24:4349–4361.
   PubMed Web of Science ®Google Scholar
• Berking, C., Takemoto, R., Schaider, H., Showe, L., Satyamoorthy, K., Robbins, P., Herlyn, M. 2001. Transforming growth factor-beta;1 increases survival of human melanoma through stroma remodeling. Cancer Res. 61:8306–8316.
   PubMed Web of Science ®Google Scholar
• Beyer, M., andSchultze, J. L. 2009. Regulatory T-cells: Major players in the tumor microenvironment. Curr. Pharm. Des. 15:1879–1892.
   PubMed Web of Science ®Google Scholar
• Blackburn, J. S., Liu, I., Coon, C. I., Brinckerhoff, C. E. 2009. A matrix metalloproteinase-1/protease activated receptor-1 signaling axis promotes melanoma invasion and metastasis. Oncogene 28:4237–4248.
   PubMedGoogle Scholar
• Blackburn, J. S., Rhodes, C. H., Coon, C. I., Brinckerhoff, C. E. 2007. RNA interference inhibition of matrix metalloproteinase-1 prevents melanoma metastasis by reducing tumor collagenase activity and angiogenesis. Cancer Res. 67:10849–10858.
   PubMed Web of Science ®Google Scholar
• Bodey, B., Bodey, B. Jr, Siegel, S. E., Kaiser, H. E. 2001. Matrix metalloproteinase expression in malignant melanomas: Tumor-extracellular matrix interactions in invasion and metastasis. In Vivo 15:57–64.
   PubMed Web of Science ®Google Scholar
• Borden, E. C., Smith, J. K., Rayman, P. A., Jacobs, B., Ireland, J., Lindner, D., Finke, J. 2010. Dual mechanistic function of MDSC subsets in melanoma resistance. J. Clin. Oncol. 28:15.
   Google Scholar
• Boumans, M. J., Houbiers, J. G., Verschueren, P., Ishikura, H., Westhovens, R., Brouwer, E., Rojkovich, B., Kelly, S., den Ade, M., Isaacs, J., Jacobs, H., Gomez-Reino, J., Holtkamp, G. M., Hastings, A., Gerlag, D. M., Tak, P. P. 2012. Safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of the monoclonal antibody ASK8007 blocking osteopontin in patients with rheumatoid arthritis: A randomized, placebo controlled, proof-of-concept study. Ann. Rheum. Dis. 71:180–185.
   PubMed Web of Science ®Google Scholar
• Braeuer, R. R., Zigler, M., Villares, G. J., Dobroff, A. S., Bar-Eli, M. 2011. Transcriptional control of melanoma metastasis: Importance of the tumor microenvironment. Semin. Cancer Biol. 21:83–88.
   PubMedGoogle Scholar
• Brekken, R. A., Puolakkainen, P., Graves, D. C., Workman, G., Lubkin, S. R., Sage, E. H. 2003. Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. J. Clin. Invest. 111:487–495.
   PubMedGoogle Scholar
• Buback, F., Renkl, A. C., Schulz, G., Weiss, J. M. 2009. Osteopontin and the skin: Multiple emerging roles in cutaneous biology and pathology. Exp. Dermatol. 18:750–759.
   PubMedGoogle Scholar
• Burton, A. L., Roach, B. A., Mays, M. P., Chen, A. F., Ginter, B. A., Vierling, A. M., Scoggins, C. R., Martin, R. C., Stromberg, A. J., Hagendoorn, L., McMasters, K. M. 2011. Prognostic significance of tumor-infiltrating lymphocytes in melanoma. Am. Surg. 77:188–192.
   PubMed Web of Science ®Google Scholar
• Carron, C. P., Meyer, D. M., Pegg, J. A., Engleman, V. W., Nickols, M. A., Settle, S. L., Westlin, W. F., Ruminski, P. G., Nickols, G. A. 1998. A peptidomimetic antagonist of the integrin α(v)β3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer Res. 58:1930–1935.
   PubMed Web of Science ®Google Scholar
• Chang, P. L., Harkins, L., Hsieh, Y. H., Hicks, P., Sappayatosok, K., Yodsanga, S., Swasdison, S., Chambers, A. F., Elmets, C. A., Ho, K. J. 2008. Osteopontin expression in normal skin and non-melanoma skin tumors. J. Histochem. Cytochem. 56:57–66.
   PubMedGoogle Scholar
• Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., Hogg, D., Lorigan, P., Lebbe, C., Jouary, T., Schadendorf, D., Ribas, A., O’Day, S. J., Sosman, J. A., Kirkwood, J. M., Eggermont, A. M., Dreno, B., Nolop, K., Li, J., Nelson, B., Hou, J., Lee, R. J., Flaherty, K. T., and Mc Arthur, G. A. 2011. BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New Engl. J. Med. 364:2507–2516.
   PubMed Web of Science ®Google Scholar
• Chaux, P., Vantomme, V., Stroobant, V., Thielemans, K., Corthals, J., Luiten, R., Eggermont, A.M., Boon, T., van der Bruggen, P. 1999. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4+ T-lymphocytes. J. Exp. Med. 189:767–778.
   PubMed Web of Science ®Google Scholar
• Chellaiah, M., Fitzgerald, C., Filardo, E. J., Cheresh, D. A., Hruska, K. A. 1996. Osteopontin activation of c-src in human melanoma cells requires the cytoplasmic domain of the integrin α(v)-subunit. Endocrinology 137:2432–2440.
   PubMedGoogle Scholar
• Chen, P., Huang, Y., Bong, R., Ding, Y., Song, N., Wang, X., Song, X., Luo, Y. 2011. Tumor-associated macrophages promote angiogenesis and melanoma growth via adrenomedullin in a paracrine and autocrine manner. Clin. Cancer Res. 17:7230–7239.
   PubMed Web of Science ®Google Scholar
• Chlenski, A., Cohn, S. L. 2010. Modulation of matrix remodeling by SPARC in neoplastic progression. Semin. Cell Dev. Biol. 21:55–65.
   PubMed Web of Science ®Google Scholar
• Chlenski, A., Guerrero, L. J., Peddinti, R., Spitz, J. A., Leonhardt, P. T., Yang, Q., Tian, Y., Salwen, H. R., Cohn, S. L. 2010. Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors. Mol. Cancer 9:138.
   PubMedGoogle Scholar
• Cipponi, A., Wieers, G., van Baren, N., Coulie, P. G. 2011. Tumor-infiltrating lymphocytes: Apparently good for melanoma patients. But why? Cancer Immunol. Immunother. 60:1153–1160.
   PubMed Web of Science ®Google Scholar
• Conway, C., Mitra, A., Jewell, R., Randerson-Moor, J., Lobo, S., Nsengimana, J., Edward, S., Sanders, D. S., Cook, M., Powell, B., Boon, A., Elliott, F., de Kort, F., Knowles, M. A., Bishop, D. T., Newton-Bishop, T. 2009. Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. J. Clin. Cancer Res. 15:6939–6946.
   Google Scholar
• Correa, M. C. Jr., Maria, D. A., Moura-da-Silva, A. M., Pizzocaro, K. F., Ruiz, I. R. 2002. Inhibition of melanoma cells tumorigenicity by the snake venom toxin jararhagin. Toxicon 40:739–748.
   PubMed Web of Science ®Google Scholar
• Dai, J., Li, B., Shi, J., Peng, L., Zhang, D., Qian, W., Hou, S., Zhao, L., Gao, J., Cao, Z., Zhao, J., Wang, H., Guo, Y. 2010. A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo. Cancer Immunol. Immunother. 59:355–366.
   PubMed Web of Science ®Google Scholar
• Dechantsreiter, M. A., Planker, E., Matha, B., Lohof, E., Holzemann, G., Jonczyk, A., Goodman, S. L., Kessler, H. 1999. N-Methylated cyclic RGD peptides as highly active and selectiveα(v)β3 integrin antagonists. J. Med. Chem. 42:3033–3040.
   PubMed Web of Science ®Google Scholar
• Deepak, P., Kumar, S., Acharya, A. 2007. Interleukin-13-induced Type II polarization of inflammatory macrophages is mediated through suppression of nuclear factor-κB and preservation of IκBα in a T-cell lymphoma. Clin. Exp. Immunol. 149:378–386.
   PubMed Web of Science ®Google Scholar
• Di Carlo, E., Forni, G., Lollini, P., Colombo, M. P., Modesti, A., Musiani, P. 2001. The intriguing role of polymorphonuclear neutrophils in anti-tumor reactions. Blood 97:339–345.
   PubMed Web of Science ®Google Scholar
• Dong, W., Li, H., Zhang, Y., Yang, H., Guo, M., Li, L., Liu, T. 2011. Matrix metalloproteinase 2 promotes cell growth and invasion in colorectal cancer. Acta Biochim. Biophys. Sin. 43:840–848.
   Google Scholar
• Duncan, L. M., Richards, L. A., Mihm, M. C. Jr. 2003. Increased mast cell density in invasive melanoma. Eur. J. Clin. Invest. 33:420–425.
   PubMedGoogle Scholar
• Duff, M. D., Mestre, J., Maddali, S., Yan, Z. P., Stapleton, P., Daly, J. M. 2007. Analysis of gene expression in the tumor-associated macrophage. J. Surg. Res. 142:119–128.
   PubMedGoogle Scholar
• Elshaw, S. R., Sisley, K., Cross, N., Murray, A. K., Mac Neil, S. M., Wagner, M., Nichols, C. E., Rennie, I. G. 2001. A comparison of ocular melanocyte and uveal melanoma cell invasion and the implication of α1β1, α4β1, and α6β1 integrins. Br. J. Ophthalmol. 85:732–738.
   PubMedGoogle Scholar
• Felding-Habermann, B., Fransvea, E., O’Toole, T. E., Manzuk, L., Faha, B., Hensler, M. 2002. Involvement of tumor cell integrin α(v)β3 in hematogenous metastasis of human melanoma cells. Clin. Exp. Metastasis 19:427–436.
   PubMed Web of Science ®Google Scholar
• Fenouille, N., Puissant, A., Tichet, M., Zimniak, G., Abbe, P., Mallavialle, A., Rocchi, S., Ortonne, J. P., Deckert, M., Ballotti, R., Tartare-Deckert, S. 2011a. SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival. Oncogene 30:4887–4900.
   PubMedGoogle Scholar
• Fenouille, N., Robert, G., Tichet, M., Puissant, A., Dufies, M., Rocchi, S., Ortonne, J. P., Deckert, M., Ballotti, R., Tartare-Deckert, S. 2011b. The p53/p21Cip1/ Waf1 pathway mediates the effects of SPARC on melanoma cell cycle progression. Pigment Cell Melanoma Res. 24:219–232.
   PubMed Web of Science ®Google Scholar
• Filipazzi, P., Valenti, R., Huber, V., Pilla, L., Canese, P., Iero, M., Castelli, C., Mariani, L., Parmiani, G., Rivoltini, L. 2007. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macro-phage colony-stimulation factor-based anti-tumor vaccine. J. Clin. Oncol. 25:2546–2553.
   PubMed Web of Science ®Google Scholar
• Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., Dummer, R., Trefzer, U., Larkin, J. M., Utikal, J., Dreno, B., Nyakas, M., Middleton, M. R., Becker, J. C., Casey, M., Sherman, L. J., Wu, F. S., Ouellet, D., Martin, A. M., Patel, K., Schadendorf, D. 2012. METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. New Engl. J. Med. 367:107–114.
   PubMed Web of Science ®Google Scholar
• Fukunaga-Kalabis, M., Martinez, G., Liu, Z. J., Kalabis, J., Mrass, P., Weninger, W., Firth, S. M., Planque, N., Perbal, B., Herlyn, M. 2006. CCN3 controls 3D spatial localization of melanocytes in the human skin through DDR1. J. Cell. Biol. 175:563–569.
   PubMed Web of Science ®Google Scholar
• Fukunaga-Kalabis, M., Martinez, G., Nguyen, T. K., Kim, D., Santiago-Walker, A., Roesch, A., Herlyn, M. 2010. Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population. Oncogene 29:6115–6124.
   Google Scholar
• Fukunaga-Kalabis, M., Martinez, G., Telson, S. M., Liu, Z. J., Balint, K., Juhasz, I., Elder, D. E., Perbal, B., Herlyn, M. 2008a. Downregulation of CCN3 expression as a potential mechanism for melanoma progression. Oncogene 27:2552–2560.
   PubMed Web of Science ®Google Scholar
• Fukunaga-Kalabis, M., Santiago-Walker, A., Herlyn M. 2008b. Matricellular proteins produced by melanocytes and melanomas: In search for functions. Cancer Microenviron. 1:93–102.
   PubMedGoogle Scholar
• Gabrilovich, D. I., Nagaraj, S. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9:162–174.
   PubMed Web of Science ®Google Scholar
• Gazzaniga, S., Bravo, A. I., Guglielmotti, A., van Rooijen, N., Maschi, F., Vecchi, A., Mantovani, A., Mordoh, J., Wainstok, R. J. 2007. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J. Invest. Dermatol. 127:2031–2041.
   PubMed Web of Science ®Google Scholar
• Ghajar, C. M., George, S. C., Putnam, A. J. 2008. Matrix metalloproteinase control of capillary morphogenesis. Crit. Rev. Eukaryot. Gene Expression 18:251–278.
   PubMedGoogle Scholar
• Gilhar, A., Ullmann, Y., Kalish, R. S., Berkutski, T., Azizi, E., Bank, I. 1997. Favourable melanoma prognosis associated with the expression of the tumor necrosis factor receptor and the α1β1 integrin: A preliminary report. Melanoma Res. 7:486–495.
   PubMedGoogle Scholar
• Ginsberg, M. H., Du, X., Plow, E. F. 1992. Inside-out integrin signaling. Curr. Opin. Cell Biol. 4:766–771.
   PubMedGoogle Scholar
• Giraudo, E., Inoue, M., Hanahan, D. 2004. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J. Clin. Invest 114:623–633.
   PubMed Web of Science ®Google Scholar
• Girotti, M. R., Fernández, M., López, J. A., Camafeita, E., Fernández, E. A., Albar, J. P., Benedetti, L. G., Valacco, M. P., Brekken, R. A., Podhajcer, O. L., Llera, A. S. 2011. SPARC promotes cathepsin B-mediated melanoma invasiveness through a collagen I/α2β1 integrin axis. J. Invest. Dermatol. 131:2438–2447.
   PubMed Web of Science ®Google Scholar
• Glukhova, L., Angevin, E., Lavialle, C., Cadot, B., Terrier-Lacombe, M. J., Perbal, B., Bernheim, A., Goguel, A. F. 2001. Patterns of specific genomic alterations associated with poor prognosis in high-grade renal cell carcinomas. Cancer Genet. Cytogenet. 130:105–110.
   PubMedGoogle Scholar
• Goh, F. G., Piccinini, A. M., Krausgruber, T., Udalova, I. A., Midwood, K. S. 2010. Transcriptional regulation of the endogenous danger signal tenascin-C: A novel autocrine loop in inflammation. J. Immunol. 184:2655–2662.
   PubMed Web of Science ®Google Scholar
• Groot Kormelink, T., Abudukelimu, A., Redegeld, F. A. 2009. Mast cells as target in cancer therapy. Curr. Pharm. Des. 15:1868–1878.
   PubMedGoogle Scholar
• Guery, J. C., Adorini, L. 1995. Dendritic cells are the most efficient in presenting endogenous naturally processed self-epitopes to Class II-restricted T-cells. J. Immunol. 154:536–544.
   PubMed Web of Science ®Google Scholar
• Gurrath, M., Muller, G., Kessler, H., Aumailley, M., Timpl, R. 1992. Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides. Eur. J. Biochem. 210:911–921.
   PubMedGoogle Scholar
• Haber, C. L., Gottifredi, V., Llera, A. S., Salvatierra, E., Prada, F., Alonso, L., Sage, E. H., Podhajcer, O. L. 2008. SPARC modulates the proliferation of stromal but not melanoma cells unless endogenous SPARC expression is down-regulated. Int. J. Cancer 122:1465–1475.
   PubMedGoogle Scholar
• Hamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Guida, M., Hyams, D. M., Gómez, H., Bastholt, L., Chasalow, S. D., Berman, D. 2011. A prospective Phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J. Transl. Med. 9:204.
   PubMedGoogle Scholar
• Hangan, D., Morris, V. L., Boeters, L., von Ballestrem, C., Uniyal, S., Chan, B. M. 1997. An epitope on VLA-6 (α6β1) integrin involved in migration but not adhesion is required for extravasation of murine melanoma B16F1 cells in liver. Cancer Res. 57:3812–3817.
   PubMed Web of Science ®Google Scholar
• Hansen, C. M., Madsen, M. W., Arensbak, B., Skak-Nielsen, T., Latini, S., Binderup, L. 1998. Down-regulation of laminin-binding integrins by 1α,25-dihydroxyvitamin D3 in human melanoma cells in vitro. Cell Adhes. Commun. 5:109–120.
   PubMed Web of Science ®Google Scholar
• Hauschild, A., Grob, J. J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H. Jr., Kaempgen, E., Martín-Algarra, S., Karaszewska, B., Mauch, C., Chiarion-Sileni, V., Martin, A. M., Swann, S., Haney, P., Mirakhur, B., Guckert, M. E., Goodman, V., Chapman, P. B. 2012. Dabrafenib in BRAF-mutated metastatic melanoma: A multi-centre, open-label, Phase 3 randomized controlled trial. Lancet 380:358–365.
   PubMed Web of Science ®Google Scholar
• Hentzen, E. R., Neelamegham, S., Kansas, G. S., Benanti, J. A., McIntire, L. V., Smith, C. W., Simon, S. I. 2000. Sequential binding of CD11a/CD18 and CD11b/CD18 defines neutrophil capture and stable adhesion to intercellular adhesion molecule-1. Blood 95:911–920.
   PubMed Web of Science ®Google Scholar
• Herwig, M. C., Grossniklaus, H. E. 2011. Role of macrophages in uveal melanoma. Expert Rev. Ophthalmol. 6:405–407.
   PubMedGoogle Scholar
• Hirai, H., Zhang, P., Dayaram, T., Hetherington, C. J., Mizuno, S., Imanishi, J., Akashi, K., Tenen, D. G. 2006. C/EBPβ is required for ‘emergency’ granulopoiesis. Nat. Immunol. 7:732–739.
   PubMed Web of Science ®Google Scholar
• Hiratsuka, S., Nakamura, K., Iwai, S., Murakami, M., Itoh, T., Kijima, H., Shipley, J. M., Senior, R. M., Shibuya, M. 2002. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2:289–300.
   PubMed Web of Science ®Google Scholar
• Hodi, F. S., Butler, M., Oble, D. A., Seiden, M. V., Haluska, F. G., Kruse, A., Macrae, S., Nelson, M., Canning, C., Lowy, I., Korman, A., Lautz, D., Russell, S., Jaklitsch, M. T., Ramaiya, N., Chen, T. C., Neuberg, D., Allison, J. P., Mihm, M. C., Dranoff, G. 2008. Immunologic and clinical effects of antibody blockade of cytotoxic T-lymphocyte-associated antigen-4 in previously-vaccinated cancer patients. Proc. Natl. Acad. Sci. USA 105:3005–3010.
   PubMed Web of Science ®Google Scholar
• Hodi, F. S., O’Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., van den Eertwegh, A. J., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbé, C., Peschel, C., Quirt, I., Clark, J. I., Wolchok, J. D., Weber, J. S., Tian, J., Yellin, M. J., Nichol, G. M., Hoos, A., Urba, W. J. 2010. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl. J. Med. 363:711–723.
   PubMed Web of Science ®Google Scholar
• Hofmann, U. B., Eggert, A. A., Blass, K., Bröcker, E. B., Becker, J. C. 2005. Stromal cells as the major source for matrix metalloproteinase-2 in cutaneous melanoma. Arch. Dermatol. Res. 297:154–160.
   PubMed Web of Science ®Google Scholar
• Horie, K., Tsuchihara, M., Nakatsura, T. 2010. Silencing of secreted protein acidic and rich in cysteine inhibits the growth of human melanoma cells with G arrest induction. Cancer Sci. 101:913–919.
   PubMed Web of Science ®Google Scholar
• Hsu, A. R., Veeravagu, A., Cai, W., Hou, L. C., Tse, V., Chen, X. 2007. Integrin α(v)β3 antagonists for anti-angiogenic cancer treatment. Recent Pat. Anticancer Drug Discov. 2:143–158.
   PubMed Web of Science ®Google Scholar
• Hussein, M. R., Elsers, D. A., Fadel, S. A., Omar, A. E. 2006. Immunohistological characterization of tumor-infiltrating lymphocytes in melanocytic skin lesions. J. Clin. Pathol. 59:316–324.
   PubMed Web of Science ®Google Scholar
• Ilkovitch, D., Lopez, D. M. 2008. Immune modulation by melanoma-derived factors. Exp. Dermatol. 17:977–985.
   PubMedGoogle Scholar
• Ilmonen, S., Jahkola, T., Turunen, J. P., Muhonen, T., Asko-Seljavaara, S. 2004. Tenascin-C in primary malignant melanoma of the skin. Histopathology 45:405–411.
   Google Scholar
• Inaba, K., Metlay, J. P., Crowley, M. T., Steinman, R. M. 1990. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific MHC-restricted T-cells in situ. J. Exp. Med. 172:631–640.
   PubMed Web of Science ®Google Scholar
• Janik, M. E., Przybyło, M., Pocheć, E., Pokrywka, M., Lityńska, A. 2010. Effect of α3β1 and α(v)β3 integrin glycosylation on interaction of melanoma cells with vitronectin. Acta Biochim. Pol. 57:55–61.
   PubMedGoogle Scholar
• Jensen, T. O., Schmidt, H., Møller, H. J., Donskov, F., Høyer, M., Sjoegren, P., Christensen, I. J., Steiniche, T. 2012. Intra-tumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC Stage I/II melanoma. Cancer 118:2476–2485.
   PubMedGoogle Scholar
• Joseph, I. B., Isaacs J. T. 1998. Macrophage role in the anti-prostate cancer response to one class of anti-angiogenic agents. JNCI 90:1648–1653.
   PubMed Web of Science ®Google Scholar
• Kääriäinen, E., Nummela, P., Soikkeli, J., Yin, M., Lukk, M., Jahkola, T., Virolainen, S., Ora, A., Ukkonen, E., Saksela, O., Hölttä, E. 2006. Switch to an invasive growth phase in melanoma is associated with tenascin-C, fibronectin, and procollagen-I-forming specific channel structures for invasion. J. Pathol. 210:181–191.
   PubMed Web of Science ®Google Scholar
• Kang, I. C., Lee, Y. D., Kim, D. S. 1999. A novel disintegrin salmosin inhibits tumor angiogenesis. Cancer Res. 59:3754–3760.
   PubMed Web of Science ®Google Scholar
• Kessenbrock, K., Plaks, V., Werb, Z. 2010. Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell 141:52–67.
   PubMed Web of Science ®Google Scholar
• Kluger, H. M., Hoyt, K., Bacchiocchi, A., Mayer, T., Kirsch, J., Kluger, Y., Sznol, M., Ariyan, S., Molinaro, A., Halaban, R. 2011. Plasma markers for identifying patients with metastatic melanoma. Clin. Cancer Res. 17:2417–2425.
   PubMedGoogle Scholar
• Knowles, H. J., Harris, A. L. 2007. Macrophages and the hypoxic tumor microenvironment. Front. Biosci. 12:4298–4314.
   PubMed Web of Science ®Google Scholar
• Kong, H. J., Mooney, D. J. 2007. Microenvironmental regulation of biomacromolecular therapies. Nat. Rev. Drug Discov. 6:455–463.
   PubMed Web of Science ®Google Scholar
• Korpos, E., Wu, C., Sorokin, L. 2009. Multiple roles of the extracellular matrix in inflammation. Curr. Pharm. Des. 15:1349–1357.
   PubMed Web of Science ®Google Scholar
• Kremser, M. E., Przybyło, M., Hoja-Łukowicz, D., Pocheć, E., Amoresano, A., Carpentieri, A., Bubka, M., Lityńska, A. 2008. Characterization of α3β1 and α(v)β3 integrin N-oligosaccharides in metastatic melanoma WM9 and WM239 cell lines. Biochim. Biophys. Acta 1780:1421–1431.
   PubMedGoogle Scholar
• Krengel, S., Stark, I., Geuchen, C., Knoppe, B., Scheel, G., Schlenke, P., Gebert, A., Wünsch, L., Brinckmann, J., Tronnier, M. 2005. Selective down-regulation of the α6 integrin subunit in melanocytes by UVB light. J. Exp. Dermatol. 14:411–419.
   PubMedGoogle Scholar
• Ledda, F., Bravo, A. I., Adris, S., Bover, L., Mordoh, J., Podhajcer, O. L. 1997a. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J. Invest. Dermatol. 108:210–214.
   PubMed Web of Science ®Google Scholar
• Ledda, M. F., Adris, S., Bravo, A. I., Kairiyama, C., Bover, L., Chernajovsky, Y., Mordoh, J., Podhajcer, O. L. 1997b. Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat. Med. 3:171–176.
   PubMed Web of Science ®Google Scholar
• Leprini, A., Querzé, G., Zardi, L. 1994. Tenascin isoforms: Possible targets for diagnosis and therapy of cancer and mechanisms regulating their expression. Perspect. Dev. Neurobiol. 2:117–123.
   PubMedGoogle Scholar
• Liang, S., Dong, C. 2008. Integrin VLA-4 enhances sialyl-Lewisx/a-negative melanoma adhesion to and extravasation through the endothelium under low flow conditions. Am. J. Physiol. 295: C 701–707.
   Google Scholar
• Liang, S., Fu, C., Wagner, D., Guo, H., Zhan, D., Dong, C., Long, M. 2008. Two-dimensional kinetics of β2-integrin and ICAM-1 bindings between neutrophils and melanoma cells in a shear flow. Am. J. Physiol. 294:C743–753.
   Google Scholar
• Likui, W., Hong, W., Shuwen, Z., Yuangang, Y., Yan, W. 2011. The potential of osteopontin as a therapeutic target for human colorectal cancer. J. Gastrointest. Surg. 15:652–659.
   PubMedGoogle Scholar
• Lin, C. Y. 2011. Matrix metalloproteinase-9 cooperates with transcription factor Snail to induce epithelial-mesenchymal transition. Cancer Sci. 102:815–827.
   PubMed Web of Science ®Google Scholar
• Lin, E. Y., Nguyen, A. V., Russell, R. G., Pollard, J. W. 2001. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193:727–740.
   PubMed Web of Science ®Google Scholar
• Liu, H., Chen, A., Guo, F., Yuan, L. 2010. A short-hairpin RNA targeting osteopontin down-regulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells. Cancer Lett. 295:27–37.
   PubMedGoogle Scholar
• Lonsdorf, A. S., Krämer, B. F., Fahrleitner, M., Schönberger, T., Gnerlich, S., Ring, S., Gehring, S., Schneider, S. W., Kruhlak, M. J., Meuth, S. G., Nieswandt, B., Gawaz, M., Enk, A. H., Langer, H. F. 2012. Engagement of αIIbβ3 (GPIIb/IIIa) with α(v)β3 integrin mediates interaction of melanoma cells with platelets: A connection to hematogenous metastasis. J. Biol. Chem. 287:2168–2178.
   PubMedGoogle Scholar
• Maillard, M., Cadot, B., Ball, R. Y., Sethia, K., Edwards, D. R., Perbal, B., Tatoud, R. 2001. Differential expression of the CCN3(nov) gene proto-oncogene in human prostate cell lines and tissues. Mol. Pathol. 54:275–280.
   PubMedGoogle Scholar
• Maloney, S. C., Marshall, J. C., Antecka, E., Orellana, M. E., Fernandes, B. F., Martins, C., Castiglione, E., Di Cesare, S., Logan, P., Burnier, M. N. Jr. 2009. SPARC is expressed in human uveal melanoma and its abrogation reduces tumor cell proliferation. Anticancer Res. 29:3059–3064.
   PubMedGoogle Scholar
• Manara, M. C., Perbal, B., Benini, S., Strammiello, R., Cerisano, V., Perdichizzi, S., Serra, M., Astolfi, A., Bertoni, F., Alami, J., Yeger, H., Picci, P., Scotlandi, K. 2002. The expression of CCN3(nov) gene in musculoskeletal tumors. Am. J. Pathol. 160:849–859.
   PubMedGoogle Scholar
• Mandruzzato, S., Solito, S., Falisi, E., Francescato, S., Chiarion-Sileni, V., Mocellin, S., Zanon, A., Rossi, C. R., Nitti, D., Bronte, V., Zanovello, P. 2009. IL4Rα+ myeloid-derived suppressor cell expansion in cancer patients. J. Immunol. 182:6562–6568.
   PubMed Web of Science ®Google Scholar
• Marcinkiewicz, C., Weinreb, P. H., Calvete, J. J., Kisiel, D. G., Mousa, S. A., Tuszynski, G. P., Lobb, R. R. 2003. Obtustatin: A potent selective inhibitor of α1β1 integrin in vitro and angiogenesis in vivo. Cancer Res. 63:2020–2023.
   PubMed Web of Science ®Google Scholar
• Mason, C. K., McFarlane, S., Johnston, P. G., Crowe, P., Erwin, P. J., Domostoj, M. M., Campbell, F. C., Manaviazar, S., Hale, K. J., El-Tanani, M. 2008. Agelastatin A: A novel inhibitor of osteopontin-mediated adhesion, invasion, and colony formation. Mol. Cancer Ther. 7:548–558.
   PubMed Web of Science ®Google Scholar
• Massi, D., Franchi, A., Borgognoni, L., Reali, U. M., Santucci, M. 1999. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum. Pathol. 30:339–344.
   PubMed Web of Science ®Google Scholar
• Meierjohann, S., Hufnagel, A., Wende, E., Kleinschmidt, M. A., Wolf, K., Friedl, P., Gaubatz, S., Schartl, M. 2010. MMP13 mediates cell cycle progression in melanocytes and melanoma cells: In vitro studies of migration and proliferation. Mol. Cancer 9:201.
   PubMedGoogle Scholar
• Melchiori, A., Mortarini, R., Carlone, S., Marchisio, P. C., Anichini, A., Noonan, D. M., Albini, A. 1995. The α3β1 integrin is involved in melanoma cell migration and invasion. Exp. Cell Res. 219:233–242.
   PubMed Web of Science ®Google Scholar
• Meyer, C., Sevko, A., Ramacher, M., Bazhin, A. V., Falk, C. S., Osen, W., Borrello, I., Kato, M., Schadendorf, D., Baniyash, M., Umansky, V. 2011. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking anti-tumor immunity in transgenic mouse melanoma model. Proc. Natl. Acad. Sci. USA 108:17111–17116.
   PubMed Web of Science ®Google Scholar
• Mhawech-Fauceglia, P., Kaya, G., Sauter, G., Mckee, T., Donze, O., Schwaller, J., Huard, B. 2006. The source of APRIL up-regulation in human solid tumor lesions. J. Leukocyte Biol. 80:697–704.
   PubMedGoogle Scholar
• Miracco, C., Mourmouras, V., Biagioli, M., Rubegni, P., Mannucci, S., Monciatti, I., Cosci, E., Tosi, P., Luzi, P. 2007. Utility of tumor-infiltrating CD25+FoxP3+ regulatory T-cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma. Oncol. Rep. 18:1115–1122.
   PubMed Web of Science ®Google Scholar
• Mitra, A., Conway, C., Walker, C., Cook, M., Powell, B., Lobo, S., Chan, M., Kissin, M., Layer, G., Smallwood, J., Ottensmeier, C., Stanley, P., Peach, H., Chong, H., Elliott, F., Iles, M. M., Nsengimana, J., Barrett, J. H., Bishop, D. T., Newton-Bishop, J. A. 2010. Melanoma sentinel node biopsy and prediction models for relapse and overall survival. Br. J. Cancer 103:1229–1236.
   PubMedGoogle Scholar
• Moretti, R. M., Montagnani Marelli, M., Mai, S., Limonta, P. 2008. Gonadotropin-releasing hormone agonists suppress melanoma cell motility and invasiveness through the inhibition of α3 integrin and MMP-2 expression and activity. Int. J. Oncol. 33:405–413.
   PubMedGoogle Scholar
• Moretti, S., Martini, L., Bert, E., Pinzi, C., Giannotti, B. 1993. Adhesion molecule profile and malignancy of melanocytic lesions. Melanoma Res. 3:235–239.
   PubMed Web of Science ®Google Scholar
• Moretti, S., Pinzi, C., Berti, E., Spallanzani, A., Chiarugi, A., Boddi, V., Reali, U. M., Giannotti, B. 1997. In situ expression of transforming growth factor-β is associated with melanoma progression and correlates with Ki67, HLA-DR and β3 integrin expression. Melanoma Res. 7:313–321.
   PubMed Web of Science ®Google Scholar
• Morgan, D. A., Ruscetti, F. W., Gallo, R. 1976. Selective in vitro growth of T-lymphocytes from normal human bone marrows. Science 193:1007–1008.
   PubMed Web of Science ®Google Scholar
• Mortarini, R., Anichini, A. 1993. From adhesion to signaling: Roles of integrins in the biology of human melanoma. Melanoma Res. 3:87–97.
   PubMed Web of Science ®Google Scholar
• Mortarini, R., Gismondi, A., Maggioni, A., Santoni, A., Herlyn, M., Anichini, A. 1995. Mitogenic activity of laminin on human melanoma and melanocytes: Different signal requirements and role of β1 integrins. Cancer Res. 55:4702–4710.
   PubMedGoogle Scholar
• Müller, R., Zheng, M., Mrowietz, U. 1997. Significant reduction of human monocyte chemotactic response to monocyte-chemotactic protein-1 in patients with primary and metastatic malignant melanoma. Exp. Dermatol. 6:81–86.
   PubMedGoogle Scholar
• Nakai, N., Hartmann, G., Kishimoto, S., Katoh, N. 2010. Dendritic cell vaccination in human melanoma: Relationships between clinical effects and vaccine parameters. Pigment Cell Melanoma Res. 23:607–619.
   PubMed Web of Science ®Google Scholar
• Nardin, A., Wong, W. C., Tow, C., Molina, T. J., Tissier, F., Audebourg, A., Garcette, M., Caignard, A., Avril, M. F., Abastado, J. P., Prévost-Blondel, A. 2011. Dacarbazine promotes stromal remodeling and lymphocyte infiltration in cutaneous melanoma lesions. J. Invest. Dermatol. 131:1896–1905.
   Google Scholar
• Nelson, A. R., Fingleton, B., Rothenberg, M. L., Matrisian, L. M. 2000. Matrix metalloproteinases: Biologic activity and clinical implications. J. Clin. Oncol. 18:1135–1149.
   PubMed Web of Science ®Google Scholar
• Nesbit, M., Herlyn, M. 1994–1995. Adhesion receptors in human melanoma progression. Invasion Metastasis. 14:131–146.
   PubMedGoogle Scholar
• Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., Schadendorf, D. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328–332.
   PubMed Web of Science ®Google Scholar
• Nevala, W. K., Vachon, C. M., Leontovich, A. A., Scott, C. G., Thompson, M. A., Markovic, S. N. 2009. Evidence of systemic TH2-driven chronic inflammation in patients with metastatic melanoma. Clin. Cancer Res. 15:1931–1939.
   PubMed Web of Science ®Google Scholar
• Nikkola, J., Vihinen, P., Vlaykova, T., Hahka-Kemppinen, M., Heino, J., Pyrhönen, S. 2004. Integrin chains β1 and α(v) as prognostic factors in human metastatic melanoma. Melanoma Res. 14:29–37.
   PubMed Web of Science ®Google Scholar
• Nuti, E., Tuccinardi, T., Rossello, A. 2007. Matrix metalloproteinase inhibitors: New challenges in the era of post broad-spectrum inhibitors. Curr. Pharm. Res. 13:2087–2100.
   PubMedGoogle Scholar
• Ostrand-Rosenberg, S. 2010. Myeloid-derived suppressor cells: More mechanisms for inhibiting anti-tumor immunity. Cancer Immunol. Immunother. 59:1593–1600.
   PubMed Web of Science ®Google Scholar
• Ozdemir, T., Zhang, P., Fu, C., Dong, C. 2012. Fibrin serves as a divalent ligand that regulates neutrophil-mediated melanoma cells adhesion to endothelium under shear condi-tions. Am. J. Physiol. 302: C 1189–1201.
   Google Scholar
• Packer, L., Pavey, S., Parker, A., Stark, M., Johansson, P., Clarke, B., Pollock, P., Ringner, M., Hayward, N. 2006. Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN. Carcinogenesis 27:1778–1786.
   PubMedGoogle Scholar
• Palena, C., Abrams, S. I., Schlom, J., Hodge, J. W. 2006. Cancer vaccines: Preclinical studies and novel strategies. Adv. Cancer Res. 95:115–145.
   PubMed Web of Science ®Google Scholar
• Palmieri, G., Capone, M., Ascierto, M. L., Gentilcore, G., Stroncek, D. F., Casula, M., Sini, M. C., Palla, M., Mozzillo, N., Ascierto, P. A. 2009. Main roads to melanoma. J. Transl. Med. 14:86–102.
   Google Scholar
• Peng, H. H., Liang, S., Henderson, A. J., Dong, C. 2007. Regulation of IL-8 expression in melanoma-stimulated neutrophil inflammatory response. Exp. Cell Res. 313:551–559.
   PubMedGoogle Scholar
• Perrotta, R., Bevelacqua, Y., Malaguarnera, G., Paladina, I., Giordano, M., Malaguarnera, M. 2010. Serum markers of cutaneous melanoma. Front. Biosci. 2:1115–1122.
   Google Scholar
• Piérard-Franchimont, C., Letawe, C., Nikkels, A. F., Piérard, G. E. 1998. Patterns of the immunohistochemical expression of melanoma-associated antigens and density of CD45R0+ activated T-lymphocytes and L1-protein+ macrophages in primary cutaneous melanomas. Int. J. Mol. Med. 2:721–724.
   PubMedGoogle Scholar
• Pocheć, E., Lityńska, A., Amoresano, A., Casbarra, A. 2003. Glycosylation profile of integrin α3β1 changes with melanoma progression. Biochim. Biophys. Acta. 1643:113–123.
   PubMed Web of Science ®Google Scholar
• Poschke, I., Mougiakakos, D., Hansson, J., Masucci, G.V., Kiessling, R. 2010. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and over-express CD80, CD83, and DC-sign. Cancer Res. 70:4335–4345.
   PubMed Web of Science ®Google Scholar
• Prada, F., Benedetti, L. G., Bravo, A. I., Alvarez, M. J., Carbone, C., Podhajcer, O. L. 2007. SPARC endogenous level, rather than fibroblast-produced SPARC or stroma reorganization induced by SPARC, is responsible for melanoma cell growth. J. Invest. Dermatol. 127:2618–2628.
   PubMed Web of Science ®Google Scholar
• Prakash, M., Kale, S., Ghosh, I., Kundu, G. C., Datta, K. 2011. Hyaluronan-binding protein 1 (HABP1/p32/gC1qR) induces melanoma cell migration and tumor growth by NF-κB-dependent MMP-2 activation through integrin α(v)β3 interaction. Cell Signal. 23:1563–1577.
   PubMed Web of Science ®Google Scholar
• Preynat-Seauve, O., Contassot, E., Schuler, P., French, L. E., Huard, B. 2007. Melanoma-infiltrating dendritic cells induce protective anti-tumor responses mediated by T-cells. Melanoma Res. 17:169–176.
   PubMedGoogle Scholar
• Preynat-Seauve, O., Schuler, P., Contassot, E., Beermann, F., Huard, B., French, L. E. 2006. Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T-cells and mediate tumor rejection. J. Immunol. 176:61–67.
   PubMed Web of Science ®Google Scholar
• Rangaswami, H., Kundu, G. C. 2007. Osteopontin stimulates melanoma growth and lung metastasis through NIK/MEKK1-dependent MMP-9 activation pathways. Oncol. Rep. 18:909–915.
   PubMed Web of Science ®Google Scholar
• Rangel, J., Nosrati, M., Torabian, S., Shaikh, L., Leong, S. P., Haqq, C., Miller, J. R. 3rd, Sagebiel, R. W., Kashani-Sabet, M. 2008. Osteopontin as a molecular prognostic marker for melanoma. Cancer 112:144–150.
   PubMed Web of Science ®Google Scholar
• Reardon, D. A., Zalutsky, M. R., Bigner, D. D. 2007. Anti-tenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev. Anticancer Ther. 7:675–687.
   PubMed Web of Science ®Google Scholar
• Redegeld, F. A., Nijkamp, F. P. 2003. Immunoglobulin free light chains and mast cells: Pivotal role in T-cell-mediated immune reactions? Trends Immunol. 24:181–185.
   PubMed Web of Science ®Google Scholar
• Reinmuth, N., Liu, W., Ahmad, S. A., Fan, F., Stoeltzing, O., Parikh, A. A., Bucana, C. D., Gallick, G. E., Nickols, M. A., Westlin, W. F., Ellis, L. M. 2003. α(v)β3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res. 63:2079–2087.
   PubMed Web of Science ®Google Scholar
• Ribatti, D., Ennas, M. G., Vacca, A., Ferreli, F., Nico, B., Orru, S., Sirigu, P. 2003. Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur. J. Clin. Invest. 33:420–425.
   PubMed Web of Science ®Google Scholar
• Robert, C., Thomas, L., Bondarenko, I., O’Day, S., Garbe, C., Lebbe, C., Baurain, J. F., Testori, A., Grob, J. J., Davidson, N., Richards, J., Maio, M., Hauschild, A., Miller, W. H. Jr, Gascon, P., Lotem, M., Harmankaya, K., Ibrahim, R., Francis, S., Chen, T. T., Humphrey, R., Hoos, A., Wolchok, J. D. 2011. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New Engl. J. Med. 364:2517–2526.
   PubMed Web of Science ®Google Scholar
• Roda, J. M., Sumner, L. A., Evans, R., Phillips, G. S., Marsh, C. B., Eubank, T. D. 2011. Hypoxia-inducible factor-2α regulates GM-CSF-derived soluble vascular endothelial growth factor receptor-1 production from macrophages and inhibits tumor growth/angiogenesis. J. Immunol. 187:1970–1976.
   PubMed Web of Science ®Google Scholar
• Rollins, B. J. 2006. Inflammatory chemokines in cancer growth and progression. Eur. J. Cancer 42:760–767.
   PubMed Web of Science ®Google Scholar
• Rothhammer, T., Hahne, J. C., Florin, A., Poser, I., Soncin, F., Wernert, N., Bosserhoff, A. K. 2004. The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma. Cell. Mol. Life Sci. 61:118–128.
   PubMedGoogle Scholar
• Roy, R., Yang, J., Moses, M. A. 2009. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol. 27:5287–5297.
   PubMed Web of Science ®Google Scholar
• Rubin, J. T., Elwood, L. J., Rosenberg, S. A., Lotze, M. T. 1989. Immunohistochemical correlates of response to recombinant IL-2-based immunotherapy in humans. Cancer Res. 49:7086–7092.
   PubMed Web of Science ®Google Scholar
• Rundhaug, J. E. 2005. Matrix metalloproteinases and angiogenesis. J. Cell. Mol. Med. 9:267–285.
   PubMed Web of Science ®Google Scholar
• Rutella, S., Danese, S., Leone, G. 2006. Tolerogenic dendritic cells: Cytokine modulation comes of age. Blood 108:1435–1440.
   PubMed Web of Science ®Google Scholar
• Ryu, B., Moriarty, W. F., Stine, M. J., De Luca, A., Kim, D. S., Meeker, A. K., Grills, L. D., Switzer, R. A., Eller, M. S., Alani, R. M. 2011. Global analysis of BRAFV600E target genes in human melanocytes identifies matrix metalloproteinase-1 as a critical mediator of melanoma growth. J. Invest. Dermatol. 131:1579–1583.
   PubMedGoogle Scholar
• Saleh, F., Renno, W., Klepacek, I., Ibrahim, G., Asfar, S., Dashti, H., Romero, P., Dashti, A., Behbehani, A. 2005. Melanoma immunotherapy: Past, present, and future. Curr. Pharm. Des. 11:3461–3434.
   PubMedGoogle Scholar
• Sanz, L., Alvarez-Vallina, L. 2005. Antibody-based anti-angiogenic cancer therapy. Expert Opin. Ther. Targets 9:1235–1245.
   PubMed Web of Science ®Google Scholar
• Schadendorf, D., Kohlmus, C., Gawlik, C., Suter, L., Czarnetzki, B. M. 1995. Mast cells in melanocytic tumors. Arch. Dermatol. Res. 287:452–456.
   PubMed Web of Science ®Google Scholar
• Schultz, J., Lorenz, P., Ibrahim, S. M., Kundt, G., Gross, G., Kunz, M. 2009. The functional -443T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-Myb transcription factor. Mol. Carcinogen. 481:14–23.
   Google Scholar
• Shen, Y. G., Xu, Y. J., Shi, Z. L., Han, H. L., Sun, D. Q., Zhang, X. 2012. Effects of RNAi-mediated matrix metalloproteinase-2 gene silencing on the invasiveness and adhesion of esophageal carcinoma cells, KYSE150. Digest. Dis. Sci. 57:32–37.
   PubMedGoogle Scholar
• Shi, L., Lei, D., Ma, C., Xu, F., Li, Y., Wang, Y., Cong, N., Liu, D., Pan, X. L. 2010. Clinicopathological implications of tumor-associated macrophages and vascularization in sinonasal melanoma. J. Int. Med. Res. 38:1276–1286.
   PubMedGoogle Scholar
• Shinohara, M. L., Kim, H. J., Kim, J. H., Garcia, V. A., Cantor, H. 2008. Alternative translation of osteopontin generates intracellular and secreted isoforms that mediate distinct biological activities in dendritic cells. Proc. Natl. Acad. Sci. USA 105:7235–7239.
   PubMedGoogle Scholar
• Sica, A., Schioppa, T., Mantovani, A., Allavena, P. 2006. Tumor-associated macrophages are a distinct M2 polarized population promoting tumor progression: Potential targets of anti-cancer therapy. Eur. J. Cancer 42:717–727.
   PubMed Web of Science ®Google Scholar
• Smit, D. J., Gardiner, B. B., Sturm, R. A. 2007. Osteonectin down-regulates E-cadherin, induces osteopontin and focal adhesion kinase activity, stimulating an invasive melanoma phenotype. Int. J. Cancer 121:2653–2660.
   PubMedGoogle Scholar
• Solinas, G., Germano, G., Mantovani, A., Allavena, P. 2009. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leukocyte Biol. 86:1065–1073.
   PubMed Web of Science ®Google Scholar
• Sorokin, L. 2010. The impact of the extracellular matrix on inflammation. Nat. Rev. Immunol. 10:712–723.
   PubMed Web of Science ®Google Scholar
• Sriramarao, P., Bourdon, M. A. 1996. Melanoma cell invasive and metastatic potential correlates with endothelial cell reorganization and tenascin expression. Endothelium 4:85–97.
   PubMedGoogle Scholar
• Steinman, R. M., Hawiger, D., Nussenzweig, M. C. 2003. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21:685–711.
   PubMed Web of Science ®Google Scholar
• Stoeltzing, O., Liu, W., Reinmuth, N., Fan, F., Parry, G. C., Parikh, A. A., Mc Carty, M. F., Bucana, C. D., Mazar, A. P., Ellis, L. M. 2003. Inhibition of integrin α 5 β1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int. J. Cancer 104:496–503.
   PubMed Web of Science ®Google Scholar
• Sturm, R. A., Satyamoorthy, K., Meier, F., Gardiner, B. B., Smit, D. J., Vaidya, B., Herlyn M. 2002. Osteonectin/SPARC induction by ectopic β3 integrin in human radial growth phase primary melanoma cells. Cancer Res. 62:226–232.
   PubMed Web of Science ®Google Scholar
• Talks, K. L., Turley, H., Gatter, K. C., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., Harris, A. L. 2000. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157:411–421.
   PubMed Web of Science ®Google Scholar
• Taylor, R. C., Patel, A., Panageas, K. S., Busam, K. J., Brady, M. S. 2007. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J. Clin. Oncol. 25:869–875.
   PubMed Web of Science ®Google Scholar
• Tazzyman, S., Lewis, C. E., Murdoch, C. 2009. Neutrophils: Key mediators of tumor angiogenesis. Int. J. Exp. Pathol. 90:222–231.
   PubMed Web of Science ®Google Scholar
• Teutschbein, J., Haydn, J. M., Samans, B., Krause, M., Eilers, M., Schartl, M., Meierjohann, S. 2010. Gene expression analysis after receptor tyrosine kinase activation reveals new potential melanoma proteins. BMC Cancer 10:386.
   PubMedGoogle Scholar
• Thorne, R. F., Marshall, J. F., Shafren, D. R., Gibson, P. G., Hart, I. R., Burns, G. F. 2000. The integrins α3β1 and α6β1 physically and functionally associate with CD36 in human melanoma cells. Requirement for the extracellular domain OF CD36. J. Biol. Chem. 75:35264–35275.
   Google Scholar
• Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., Leming, P. D., Spigel, D. R., Antonia, S. J., Horn, L., Drake, C. G., Pardoll, D. M., Chen, L., Sharfman, W. H., Anders, R. A., Taube, J. M., McMiller, T. L., Xu, H., Korman, A. J., Jure-Kunkel, M., Agrawal, S., McDonald, D., Kollia, G. D., Gupta, A., Wigginton, J. M., Sznol, M. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New Engl. J. Med. 366:2443–2454.
   PubMed Web of Science ®Google Scholar
• Trikha, M., De Clerck, Y. A., Markland, F. S. 1994. Contortrostatin, a snake venom disintegrin, inhibits β1 integrin-mediated human metastatic melanoma cell adhesion and blocks experimental metastasis. Cancer Res. 54:4993–4998.
   PubMed Web of Science ®Google Scholar
• Trikha, M., Zhou, Z., Nemeth, J. A., Chen, Q., Sharp, C., Emmell, E., Giles-Komar, J., Nakada, M. T. 2004. CNTO 95, a fully-human monoclonal antibody that inhibits α(v) integrins, has anti-tumor and anti-angiogenic activity in vivo. Int. J. Cancer 110:326–335.
   PubMed Web of Science ®Google Scholar
• Tronnier, M. 2000. Expression of α3β1 integrin in suprabasal layers of the epidermis of melanocytic tumors is due to epithelial hyperproliferation. J. Cutan. Pathol. 27:202–203.
   PubMedGoogle Scholar
• Tsuji, T., Kawada, Y., Kai-Murozono, M., Komatsu, S., Han, S. A., Takeuchi, K., Mizushima, H., Miyazaki, K., Irimura, T. 2002. Regulation of melanoma cell migration and invasion by laminin-5 and α3β1 integrin (VLA-3). Clin. Exp. Metastasis 19:127–134.
   PubMed Web of Science ®Google Scholar
• Tsung, A. J., Kargiotis, O., Chetty, C., Lakka, S. S., Gujrati, M., Spomar, D. G., Dinh, D. H., Rao, J. S. 2008. Down-regulation of matrix metalloproteinase-2 (MMP-2) utilizing adenovirus-mediated transfer of small interfering RNA (siRNA) in a novel spinal metastatic melanoma model. Int. J. Oncol. 32:557–564.
   PubMed Web of Science ®Google Scholar
• Udalova, I. A., Ruhmann, M., Thomson, S. J., Midwood, K. S. 2011. Expression and immune function of tenascin-C. Crit. Rev. Immunol. 31:115–145.
   PubMed Web of Science ®Google Scholar
• Uehara, H., Luo, L., Simonis, J., Singh, N., Taylor, E. W., Ambati, B. K. 2010. Anti-SPARC oligopeptide inhibits laser-induced CNV in mice. Vision Res. 50:674–679.
   PubMedGoogle Scholar
• Väisänen, A., Kallioinen, M., Taskinen, P. J., Turpeenniemi-Hujanen, T. 1998. Prognostic value of MMP-2 immunoreactive protein (72 kD Type IV collagenase) in primary skin melanoma. J. Pathol. 186:51–58.
   PubMed Web of Science ®Google Scholar
• Väisänen, A. H., Kallioinen, M., Turpeenniemi-Hujanen, T. 2008. Comparison of the prognostic value of matrix metalloproteinases-2 and -9 in cutaneous melanoma. Hum. Pathol. 39:377–385.
   PubMedGoogle Scholar
• Vallacchi, V., Daniotti, M., Ratti, F., Di Stasi, D., Deho, P., De Filippo, A., Tragni, G., Balsari, A., Carbone, A., Rivoltini, L., Parmiani, G., Lazar, N., Perbal, B., Rodolfo, M. 2008. CCN3/nephroblastoma over-expressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma. Cancer Res. 68:715–723.
   PubMed Web of Science ®Google Scholar
• Vallacchi, V., Rodolfo, M. 2009. Regulatory role of CCN3 in melanoma cell interaction with the extracellular matrix. Cell Adh. Migr. 3:7–10.
   PubMed Web of Science ®Google Scholar
• van Kilsdonk, J. W., Takahashi, N., Weidle, U., Burtscher, H., Jarry, J., Daha, M. R., Swart, G. W., van Kempen, L. C. 2012. Modulation of activated leukocyte cell adhesion molecule-mediated invasion triggers an innate immune gene response in melanoma. J. Invest. Dermatol. 132:1462–1470.
   PubMedGoogle Scholar
• van Obberghen-Schilling, E., Tucker, R. P., Saupe, F., Gasser, I., Cseh, B., Orend, G. 2011. Fibro-nectin and tenascin-C: Accomplices in vascular morphogenesis during development and tumor growth. Int. J. Dev. Biol. 55:511–525.
   PubMedGoogle Scholar
• van Pel, A., van der Bruggen, P., Coulie, P. G., Brichard, V. G., Lethé, B., van den Eynde, B., Uyttenhove, C., Renauld, J. C., Boon, T. 1995. Genes coding for tumor antigens recognized by cytolytic T-lymphocytes. Immunol. Rev. 145:229–250.
   PubMed Web of Science ®Google Scholar
• Varney, M. L., Olsen, K. J., Mosley, R. L., Bucana, C. D., Talmadge, J. E., Singh, R. K. 2002. Monocyte/macrophage recruitment, activation, and differentiation modulate IL-8 production: A paracrine role of tumor-associated macrophages in tumor angiogenesis. In Vivo 16:471–477.
   PubMed Web of Science ®Google Scholar
• Varney, M. L., Olsen, K. J., Mosley, R. L., Singh, R. K. 2005. Paracrine regulation of vascular endothelial growth factor-α expression during macrophage-melanoma cell interaction: Role of monocyte chemotactic protein-1 and macrophage colony-stimulating factor. J. Interferon Cytokine Res. 25:674–683.
   PubMed Web of Science ®Google Scholar
• Vendramini-Costa, D. B., Carvalho, J. E. 2012. Molecular link mechanisms between inflammation and cancer. Curr. Pharm. Des. 18:3831–3852.
   PubMed Web of Science ®Google Scholar
• Vihinen, P., Koskivuo, I., Syrjänen, K., Tervahartiala, T., Sorsa, T., Pyrhönen, S. 2008. Serum matrix metalloproteinase-8 is associated with ulceration and vascular invasion of malignant melanoma. Melanoma Res. 18:268–273.
   PubMed Web of Science ®Google Scholar
• Voura, E. B., Ramjeesingh, R. A., Montgomery, A. M. 2001. Involvement of integrin α(v)β3 and cell adhesion molecule L1 in trans-endothelial migration of melanoma cells. Siu CH. Mol. Biol. Cell. 12:2699–2710.
   PubMed Web of Science ®Google Scholar
• Wagner, S. N., Schultewolter, T., Wagner, C., Briedigkeit, L., Becker, J. C., Kwasnicka, H. M., Goos, M. 1998. Immune response against human primary malignant melanoma: A distinct cytokine mRNA profile associated with spontaneous regression. Lab. Invest. 78:541–550.
   PubMed Web of Science ®Google Scholar
• Wai Wong, C., Dye, D.E ,andCoombe, D. R. 2012. The role of immunoglobulin superfamily cell adhesion molecules in cancer metastasis. Int. J. Cell Biol. 2012:340296.
   PubMedGoogle Scholar
• Wang, T., Ge, Y., Xiao, M., Lopez-Coral, A., Azuma, R., Somasundaram, R., Zhang, G., Wei, Z., Xu, X., Rauscher, F. J. 3rd, Herlyn, M., Kaufman, R. E. 2012. Melanoma-derived conditioned media efficiently induce the differentiation of monocytes to macrophages that display a highly-invasive gene signature. Pigment Cell Melanoma Res. 25:493–505.
   PubMedGoogle Scholar
• Wang, Y. C., He, F., Feng, F., Liu, X. W., Dong, G. Y., Qin, H. Y., Hu, X. B., Zheng, M. H., Liang, L., Feng, L., Liang, Y. M., Han, H. 2010. Notch signaling determines the M1 vs. M2 polarization of macrophages in anti-tumor immune responses. Cancer Res. 70:4840–4849.
   PubMed Web of Science ®Google Scholar
• Weidle, U. H., Maisel, D., Klostermann, S., Weiss, E. H., Schmitt, M. 2011. Differential splicing generates new transmembrane receptor and extracellular matrix-related targets for antibody-based therapy of cancer. Cancer Genomics Proteomics 8:211–226.
   PubMedGoogle Scholar
• Wierzbicka-Patynowski, I., Niewiarowski, S., Marcinkiewicz, C., Calvete, J. J., Marcinkiewicz, M. M., McLane, M. A. 1999. Structural requirements of echistatin for the recognition of α(v)β3 and α5β1 integrins. J. Biol. Chem. 274:37809–37814.
   PubMed Web of Science ®Google Scholar
• Wolf, J. E. Jr. 1975. Tumor angiogenic factor and human skin tumors. Jr. Arch. Dermatol. 111:321–327.
   PubMed Web of Science ®Google Scholar
• Yang, L., De Busk, L. M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., Matrisian, L. M., Carbone, D. P., Lin, P. C. 2004. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell. 6:409–421.
   PubMed Web of Science ®Google Scholar
• Yang, L., Huang, J., Ren, X., Gorska, A. E., Chytil, A., Aakre, M., Carbone, D. P., Matrisian, L. M., Richmond, A., Lin, P. C., Moses, H. L. 2008. Abrogation of TGFβ signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell. 13:23–35.
   PubMed Web of Science ®Google Scholar
• Yazdi, A. S., Morstedt, K., Puchta, U., Ghoreschi, K., Flaig, M. J., Rocken, M., Sander, C. A. 2006. Heterogeneity of T-cell clones infiltrating primary malignant melanomas. J. Invest. Dermatol. 126:393–398.
   PubMedGoogle Scholar
• Ye, X., Yang, D. 2009. Recent advances in biological strategies for targeted drug delivery. Cardiovasc. Hematol. Disord. Drug Targets 9:206–221.
   PubMedGoogle Scholar
• Zamarron, B. F., Chen, W. 2011. Dual roles of immune cells and their factors in cancer development and progression. Int. J. Biol. Sci. 7:651–658.
   PubMed Web of Science ®Google Scholar
• Zhang, P., Ozdemir, T., Chung, C. Y., Robertson, G. P., Dong, C. 2011a. Sequential binding of α(v)β3 and ICAM-1 determines fibrin-mediated melanoma capture and stable adhesion to CD11b/CD18 on neutrophils. J. Immunol. 186:242–254.
   PubMedGoogle Scholar
• Zhang, Y., Forootan, S. S., Kamalian, L., Bao, Z. Z., Malki, M. I., Foster, C. S., Ke, Y. 2011b. Suppressing tumorigenicity of prostate cancer cells by inhibiting osteopontin expression. Int. J. Oncol. 38:1083–1091.
   PubMed Web of Science ®Google Scholar
• Zhang, Z., Ramirez, N. E., Yankeelov, T. E., Li, Z., Ford, L. E., Qi, Y., Pozzi, A., Zutter, M. M. 2008. α2β1 integrin expression in the tumor microenvironment enhances tumor angiogenesis in a tumor cell-specific manner. Blood 111:1980–1988.
   PubMedGoogle Scholar
• Zhao, W., Wang, L., Zhang, L., Yuan, C., Kuo, P. C., Gao, C. 2010. Differential expression of intracellular and secreted osteopontin isoforms by murine macrophages in response to toll-like receptor agonists. J. Biol. Chem. 285:20452–20461.
   PubMedGoogle Scholar
• Zhou, Y., Dai, D. L., Martinka, M., Su, M., Zhang, Y., Campos, E. I., Dorocicz, I., Tang, L., Huntsman, D., Nelson, C., Ho, V., Li, G. J. 2005. Osteopontin expression correlates with melanoma invasion. J. Invest. Dermatol. 124:1044–1052.
   PubMedGoogle Scholar
• Zhu, T. N., He, H. J., Kole, S., D’Souza, T., Agarwal, R., Morin, P. J., Bernier, M. 2007. Filamin A-mediated down-regulation of the exchange factor Ras-GRF1 correlates with decreased matrix metalloproteinase-9 expression in human melanoma cells. J. Biol. Chem. 282:14816–14826.
   PubMed Web of Science ®Google Scholar
• Zigrino, P., Kuhn, I., Bäuerle, T., Zamek, J., Fox, J. W., Neumann, S., Licht, A., Schorpp-Kistner, M., Angel, P., Mauch, C. 2009. Stromal expression of MMP-13 is required for melanoma invasion and metastasis. J. Invest. Dermatol. 129:2686–2693.
   PubMed Web of Science ®Google Scholar
• Ziober, B. L., Chen, Y. Q., Ramos, D. M., Waleh, N., Kramer, R. H. 1999. Expression of the α7β1 laminin receptor suppresses melanoma growth and metastatic potential. Cell Growth Differ. 10:479–490.
   PubMedGoogle Scholar
• Zukiel, R., Nowak, S., Wyszko, E., Rolle, K., Gawronska, I., Barciszewska, M. Z., Barciszewski, J. 2006. Suppression of human brain tumor with interference RNA specific for tenascin-C. Cancer Biol. Ther. 5:1002–1007.
   PubMed Web of Science ®Google Scholar